Programme

The Virus Molecular Interactions: Therapeutic Targets programme follows. For the programme that was delivered at the event including timings, please download the pdf from this page.

Session 1: Virus particle structure and entry

Antibody neutralization of HIV
Dennis Burton*
The Scripps Research Institute, California, USA

Locks and keys for herpes simplex virus entry into cells
Patricia Spear*
Northwestern University, USA 

Systems biology of virus entry in mammalian cells
Lucas Pelkmans*
ETH-Hönggerberg, Zürich, Switzerland 

Antiviral aptamers
William James*
University of Oxford, UK 

A metallopeptide mimic of the coiled coil domain of class 1 viruses is a useful target for antiviral drugs
Lifeng Cai, Yanxia Hou and Miriam Gochin*
Touro University - California, USA 

Two-color fluorescence analysis of individual virions determines the distribution of copy number of proteins in herpes simplex virus particles
Richard W Clarke, Haitao Li, Dejian Zhou, Helena Browne, David Klenerman*
University of Cambridge, UK

Session 2: Innate defences and cellular interactions

Seeking antiviral factors: tripartite motif proteins and cyclophilins
Greg Towers*
University College London, UK 

Interfering with interferon: lessons from paramyxoviruses and pestiviruses
Steve Goodburn*
St George's University of London, UK 

A new inhibitor of apoptosis from vaccinia virus and eukaryotes
Caroline I Gubser*
Imperial College, London, UK 

Breaking the silence: synthetic and immunological approaches to the design of carbohydrate immunogens for HIV - 1
C N Scanlan*, C Dunlop, H K Lee, S Tully, J Offer, D Harvey, D Calarese, K Baruah, O Blixt, M Crispin, C H Wong, P M Rudd, P Wentworth, N Zitzmann, D R Burton and R A Dwek
University of Oxford, UK 

Characterization of the LEDGF/p75 binding site in HIV-1 integrase
Katrien Busschots*, Anneleen Hombrouck, Jan De Rijck, Arnout Voet, Jelle Hendrix, Marc De Maeyer, Yves Engelborghs, Frauke Christ and Zeger Debyser
Katholieke Universiteit Leuven, Belgium

Session 3: Antiviral drug development

HCV infection: antiviral approaches
Richard Bethell*
Boehringer Ingelheim (Canada) Ltd., Canada 

15 years of NNRTI research: how scientists resist the viral escape
Piet Wigerinck*
Tibotec BVBA, Belgium 

Adenovirus proteinase - multiple targets for antiviral therapy
Walter F Mangel*
Brookhaven National Laboratory, New York, USA 

Structure-based design of GSK625433: A novel clinical candidate for treatment of HCV
D Haigh*, E M Amphlett, G S Bravi, H Bright, V Chung, C Chambers, A G Cheasty, M A Convery, M R Ellis, R Fenwick, D F Gray, C D Hartley, P D Howes, R L Jarvest, K J Medhurst, A Mehbob, D Mesogiti, F Mirzai, F Nerozzi, N R Parry, N A Roughley, T J Skarzynski, M J Slater, S A Smith, R Stocker, C J Theobald, P J Thomas, P A Thommes, J H Thorpe, C S Wilkinson and E Williams
GlaxoSmithKline, UK 

Identification of potent small-molecule inhibitors of arenavirus infection by high-throughput screening
Andrew M Lee, Jillian M Rojek, Alex Shaginian, Christina F Spiropoulou, Dale L Boger, Michael B A Oldstone and Stefan Kunz*
Scripps Research Institute, USA 

Novel amphipathic DNA polymers REP 9 and REP 9C display activity in vivo against H5N1 and other influenza strains
Andrew Vaillant*, Olivier Ferraris, Jean-Marc Juteau, Annie Lebel, Nathalie Goyette, Guy Boivin, Bruno Lina, Michael Holbrook and Phil Wyde
REPLICor Inc., Quebec, Canada 

Session 4: Structures of viral proteins and nucleic acids

Viral membrane fusion proteins: how many structural classes?
Félix A Rey*
Laboratoire de Virologie Moléculaire & Structurale, CNRS-INRA and IFR 115, France 

Insights and therapeutic opportunities in structural virology
David Stuart*
The Wellcome Trust Centre for Human Genetics, Oxford, UK 

Title TBC
James Hogle*
Harvard University, Boston, USA 

Structural analysis of the HIV-1 packaging signal reveal novel protein binding sites and regions susceptible to antiviral intervention
AML Lever*, J Greatorex, E Anderson, M Gait, D Brown, J Gallego, R Pomerantz and S Lea
University of Cambridge, UK 

RNA genome recognition & packaging and hidden symmetry constraints: new opportunities for anti viral therapy
Peter G Stockley*, Alison E Ashcroft, Gabriela Basnak, Bo Meng, David H J Bunka, Claire Bullock, James M Hogle, Stephen W Homans, Tom Keef, Stephen Lane, Simon E V Phillips, Neil Ranson, Ottar Rolfsson, David J Rowlands, Nicola J Stonehouse, Gary S Thompson, Katerina Toropova, Toby J Tuthill and Reidun Twarock
University of Leeds, UK 

Crystallographic and functional analysis of foot-and-mouth disease virus 3C protease reveal the structural basis of substrate and inhibitor specificity
Trevor R Sweeney, Patricia A Zunszain, Núria Roqué-Rosell, Robin J Leatherbarrow and Stephen Curry*
Imperial College, London, UK 

 

* denotes presenter to whom affiliation applies